revious studies have demonstrated that combined therapy with aspirin and ticlopidine can synergically inhibit platelet reactivity, and thus substantially reduce the incidence of early ischemic events following coronary artery stenting. 1-3 However, acute or subacute stent thrombosis still occurs in up to 1-2% of patients, especially soon after stent implantation, 1,2 and it has been suggested that this phenomenon is caused by the delayed onset of the antiplatelet effect of ticlopidine. 4 Clopidogrel, a new thienopyridine derivative that is chemically related to ticlopidine, blocks platelet activation by selectively and irreversibly inhibiting the binding of adenosine diphosphate (ADP) to its receptor on platelets, and subsequently inhibiting the ADP-dependent activation of the Gp IIb-IIIa complex, the major receptor for fibrinogen binding on platelet surface. 5 Some recent studies have shown that clopidogrel, particularly as a loading dose of 300 mg, can rapidly and significantly inhibit platelet aggregation in both healthy subjects and patients with atherosclerotic disease, even after just 2 h. 6-8 Thus, such a loading dose, followed by daily doses of 75 mg, has become one of the most popular regimens for patients after coronary stenting in our clinical practice. However, a more recent study has demonstrated that the conventional loading dose in patients with unstable angina (UA) undergoing coronary stenting inhibited no more than 40% of ADP (20 g) induced platelet aggregation within the first 4 h, whereas a loading dose of 600 mg of clopidogrel more substantially inhibited ADP (20 g) induced platelet aggregation. 4 These findings 4,6-8 raise suspicions regarding which dose regimen is most suitable for patients, particularly those with acute coronary syndrome (ACS) and platelet hyperreactivity who are undergoing coronary stenting.
revious studies have demonstrated that combined therapy with aspirin and ticlopidine can synergically inhibit platelet reactivity, and thus substantially reduce the incidence of early ischemic events following coronary artery stenting. [1] [2] [3] However, acute or subacute stent thrombosis still occurs in up to 1-2% of patients, especially soon after stent implantation, 1, 2 and it has been suggested that this phenomenon is caused by the delayed onset of the antiplatelet effect of ticlopidine. 4 Clopidogrel, a new thienopyridine derivative that is chemically related to ticlopidine, blocks platelet activation by selectively and irreversibly inhibiting the binding of adenosine diphosphate (ADP) to its receptor on platelets, and subsequently inhibiting the ADP-dependent activation of the Gp IIb-IIIa complex, the major receptor for fibrinogen binding on platelet surface. 5 Some recent studies have shown that clopidogrel, particularly as a loading dose of 300 mg, can rapidly and significantly inhibit platelet aggregation in both healthy subjects and patients with atherosclerotic disease, even after just 2 h. [6] [7] [8] Thus, such a loading dose, followed by daily doses of 75 mg, has become one of the most popular regimens for patients after coronary stenting in our clinical practice. However, a more recent study has demonstrated that the conventional loading dose in patients with unstable angina (UA) undergoing coronary stenting inhibited no more than 40% of ADP (20 g) induced platelet aggregation within the first 4 h, whereas a loading dose of 600 mg of clopidogrel more substantially inhibited ADP (20 g) induced platelet aggregation. 4 These findings 4,6-8 raise suspicions regarding which dose regimen is most suitable for patients, particularly those with acute coronary syndrome (ACS) and platelet hyperreactivity who are undergoing coronary stenting.
The ADP stimulation test, a physiologic assay that can provide information regarding platelet aggregation ability, is well established in various clinical settings. 4, [6] [7] [8] However, the CD62p expression test using flow cytometry, which can provide essential information on platelet activation, has not been fully investigated in patients with UA or other clinical settings. Furthermore, data are not available regarding the serial changes in platelet activation after a loading dose of 300 mg of clopidogrel therapy, followed by daily doses of 75 mg, in the clinical setting of UA. This is very important for physicians in their daily clinical practice, because platelet activation is a hallmark of ACS, [9] [10] [11] and formed the basis of the present study.
Background Platelet activation is crucial in the development of acute or subacute stent thrombosis following implantation. This study investigated whether a conventional regimen comprising a loading dose of 300 mg of clopidogrel, followed by daily doses of 75 mg, could significantly suppress platelet activation in patients with unstable angina (UA) undergoing coronary stenting.
Methods and Results
Platelet activation (expressed by CD62p) was serially examined using flow cytometry in 42 consecutive patients with UA who underwent coronary stenting. CD62p expression was also evaluated in 30 normal control subjects. CD62p expression was markedly higher pre-procedure in the study patients than in the normal control subjects (5.2±4.0% vs 1.4±0.6%, p<0.0001). CD62p expression in the study patients remained significantly higher at 24 h after the procedure than in the control subjects (3.8±2.1% vs 1.4±0.6%, p<0.001). Additionally, only 26% of CD62p expression (5.2% vs 3.8%, p=0.026) in the study patients was suppressed at 24 h after the procedure. However, more than 60% of CD62p expression (5.2% vs 2.0%, p<0.0001) was suppressed on day 7 after the procedure. Conclusion Less than one-third of CD62p expression was suppressed at 24 h by the conventional loading dose (300 mg) of clopidogrel in patients with UA following coronary stenting. This finding indicates the need to evaluate whether an increased loading dose of clopidogrel would be a more efficacious and safe regimen for patients in this clinical setting. 
Methods

Patient Population and Inclusion Criteria
Between July 2004 and October 2004, 42 consecutive patients suffering UA who underwent elective coronary artery stenting of new non-obstructive lesions were enrolled. For the purpose of this study, platelet activity of all patients was prospectively measured by flow cytometry.
To avoid other possible influences on platelet reactivity, patients with abnormal liver function, renal insufficiency (creatinine >1.5 mg/dl), malignancy, febrile disorders, and acute or chronic inflammatory disease were excluded, as well as those with a history of atrial fibrillation, valvular heart disease, history of recent infection, procedure-related myocardial infarction (MI) and also those with acute MI onset of <3 months. Patients were excluded if they were receiving adjunctive tirofiban or clopidogrel therapy prior to blood sampling because the potential impact of these drugs on platelet activity was impossible to determine. However, patients who received heparin or low-molecularweight heparin before blood sampling were not excluded. Patients with persistent chest pain and ischemic ST-change on ECG and requiring either urgent or emergency cardiac catheterization were also excluded. Finally, patients were also excluded if fever (body temperature >37.5°C) was observed before cardiac catheterization. The lesion had to be a new one that had not undergone prior coronary angioplasty.
Thirty age-and gender-matched healthy volunteers were studied as the control group. All subjects gave informed consent and the protocol was approved by the Institutional Review Committee on Human Research.
Blood Sampling and Assessment of Platelet Activity
A 4 ml blood sample was obtained once from the normal control subjects at the health examination center of the hospital. For the study patients, blood samples were immediately drawn following vascular puncture in the cardiac catheterization room, then at 24 h during hospitalization, and again on day 7 after coronary artery stenting in the outpatient department from the antecubital vein under minimal tourniquet pressure and with a single attempt using a sterile 22-gauge needle syringe and vacutainer containing 3.8% buffered sodium citrate. The samples were centrifuged (model 5400; Kubota Corp; Tokyo; Japan) for 15 min at 1,500 rpm at room temperature and the supernatant platelet-rich plasma was used for the assessment of platelet activity. The time between blood collection and antibody labeling was <30 min.
Platelet activity was determined with respect to -granule degranulation (surface expression of P-selectin or the CD62p antigen). Details of the procedure have been described previously. 12 Briefly, a fluorescein isothiocyanateconjugated antibody to glycoprotein IIIa (CD61; Becton Dickinson, San Jose, CA, USA) was used as an activationindependent marker of platelets. A phycoerythrin (PE)-conjugated anti-CD62 antibody (Becton Dickinson) was used to assess -granule degranulation. The association of ligands with platelets was determined using a fluorescenceactivated cell sorter (FACSCalibur™ system; Becton Dickinson). The control ligand (IgG-PE conjugate) was used to detect any nonspecific association and to permit the establishment of a threshold for activation-dependent binding. The percentage of platelets expressing P-selectin was defined as the fraction exhibiting specific binding (ie, being CD62p positive) minus that exhibiting nonspecific binding (ie, the percentage defined with the IgG-PE conjugate) of the 10,000 platelets sorted. The assays for P-selectin expression in each blood sample were performed in duplicate and the mean was recorded.
Procedure and Protocol
A transradial artery approach using a 6-French arterial sheath and a 6-F Kimny Miniradi (Boston Scientific, Scimed, Maple Grove, MN, USA) was routinely utilized for both coronary angiography and the percutaneous coronary intervention (PCI) except in cases with a positive Allen's test. The medications shown in Table 1 were initially administered to the patients upon presentation. Clopidogrel (300 mg of loading dose after stenting, then 75 mg/day) was administered for at least 4 weeks to all patients following stenting and aspirin (100 mg orally once daily) was administered to each patient indefinitely. None of the normal control subjects was given these medications.
Statistical Analysis
Categorical variables were compared using the chisquare test and continuous variables were compared using a t-test. Logarithm transformation of high-sensitivity Creactive protein (hs-CRP) and CD62p expression was used to improve the normality for statistical analysis. Continuous variables of CD62p expression among 3 intervals (preprocedure time, at 24 h and on day 7) were compared using repeated measures of ANOVA, and Scheffe's multiple comparison was used for further comparing the mean different intervals. Statistical analysis used SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC, USA). A p-value <0.05 was considered statistically significant. Table 1 lists the baseline characteristics of study patients and control subjects. There were no significant differences in terms of age, gender, body temperature, or creatinine or calcium concentrations. Mean platelet counts and white blood cell (WBC) counts were within normal range in both study patients and normal control subjects. Platelet counts were significantly lower in the study patients compared with the control subjects (p<0.0004). However, WBC counts were significantly higher in the study patients than in the normal control subjects (p<0.0001). Moreover, hs-CRP was markedly higher in the study patients than in the normal control subjects (p<0.0001). Furthermore, CD62p expression was substantially higher in the study patients compared with the normal control subjects (p<0.0001).
Results
Baseline Characteristics and Laboratory Findings of Study Patients and Normal Control Groups
No 30-day major adverse cardiac events (defined as recurrent chest pain, recurrent ischemia, new onset of Q or non-Q wave MI, repeated target vessel revascularization or 30-day death) occurred during clinical follow-up. Table 2 shows the serial changes in platelet activity (CD62p expression) in the study patients. The intra-assay variability based on repeated measurements of the same blood sample was low, with mean coefficients of variance <7.0% in our laboratory.
Serial Changes in theCirculating WBC and Platelet Counts and Platelet Activity
CD62p expression was markedly higher pre-procedure in the study patients than in the normal control subjects (5.2±4.0% vs 1.4±0.6%, p<0.0001). CD62p expression in study patients remained significantly higher at 24 h after the procedure than in the control subjects (3.8±2.1% vs 1.4%, p<0.001). Additionally, only 26% of CD62p expression (5.2% vs 3.8%, p=0.026) in the study patients was suppressed at 24 h after the procedure. However, more than 60% of CD62p expression (5.2% vs 2.0%, p<0.0001) was suppressed on day 7 after the procedure. Furthermore, CD62p expression did not differ between study patients and normal control subjects on day 7 after the procedure (2.0±0.9% vs 1.4±0.6%, p>0.1).
There were no significant differences in terms of WBC or platelets counts at the 3 time points in the study patients (all p-values >0.1).
Discussion
Platelet activity is noticeably increased following ACS, [9] [10] [11] 13 and PCI, 14 and numerous studies have demonstrated that platelet activation plays an important role in thrombus formation in various clinical settings, resulting in unfavorable clinical outcomes. 1, 14, 15 Therefore, inhibition of platelet aggregation is believed to be crucial for the strategic management of primary and secondary prevention of thromboembolic events in high-risk patients. 1, [15] [16] [17] One important finding of the present study was that the CD62p expression was substantially higher pre-procedure in the study patients than in the normal control subjects, which is important information for the management of patients with ACS.
Previous clinical trials showed that early use of potent anti-platelet agents gave most clinical benefit to patients with ACS; 16, 17 however, the efficacy of these anti-platelet therapies for secondary prevention following ACS was not based on measuring platelet activity in individual patients, but rather on clinical observation. 1, 2, 5, 16, 17 Therefore, the findings of the present study are clinically important because they reinforce the rationale of strategic management based on the finding of the previous studies. 1, 2, 4, 16, 17 Basic investigations have shown that CRP is not only an inflammatory biomarker but also mediates atherosclerosis, because it directly participates in the pathogenesis of lesion formation, plaque rupture and coronary thrombosis by interacting with and alternating the endothelial cell phenotype. 18 The present study found that WBC counts and hs-CRP, the indexes of inflammatory makers, were markedly elevated in the pre-procedural phase, which indicates that the patients were in an acute inflammatory condition that undoubtedly directly participated in the enhancement of platelet reactivation. Our most important finding was that only 26% of CD62p expression was suppressed at 24 h after the procedure, which indicates that a loading dose of 300 mg of clopidogrel, the most popular strategic management in daily clinical practice, is insufficient for patients with UA undergoing coronary stenting. Recently, Iris et al demonstrated that a loading dose of 300 mg of clopidogrel could only inhibit less than 40% of ADP (20 g) induced platelet aggregation within the first 4 h in patients with stable angina undergoing coronary stenting. 4 Notably, partial recovery of platelet aggregation at 24 h was observed in their patients. 4 On the other hand, a loading dose of 600 mg of clopidogrel substantially inhibited ADP (20 g) induced platelet aggregation within the first 4 h and there was a sustained steadystate level of inhibition of platelet aggregation. 4 However, when thrombin-related activating peptide, a strong agonist of platelet aggregation, was used to stimulate platelets, only weak inhibition of platelet aggregation was observed in their patients throughout the observation period. 4 This in vitro test for measuring the ability of platelet reactivity imitates the conditions under which platelets are activated in patients with UA 4 and could explain why platelet activation was still remarkably higher at 24 h after coronary stenting in our patients.
Another important finding of our study was that the CD62p expression declined substantially within 1 week, which was consistent with recent studies, 4,6-8 and could explain why previous studies found that most cases of acute or subacute stent thrombosis occur within a few days of stent implantation. 1, 2 This is new clinical information that patients with ACS, especially those with ST-segment elevated MI, are in a higher thrombogenic stage in the early days after coronary stenting.
Study Limitations
First, the sample size is relatively small, but the results are impressive. Furthermore, this study remains one of the largest cohort studies to use flow cytometry to serially measure platelet activation in patients with UA undergoing coronary stenting. Second, without using the ADP stimulation test, this study could not provide additional data regarding platelet activation. Third, clopidogrel was not administered and CD62p expression was not tested in the same manner in the normal control subjects as in the study patients. Thus, this study did not provide the clopidogrel responses in these volunteers. Fourth, this study was not designed to investigate the link between platelet activity and long-term outcomes in patients with UA after coronary stenting, so we did not provide additional information other than the suppression of CD62p expression by clopidogrel. Finally, the effects of aspirin, statins and angiotensinconverting enzyme inhibitors on suppression of baseline circulating concentrations of hs-CRP and platelet activity could not be completely ruled out, but would be minimal because they were administered to our patients for less than 48 h.
In conclusion, platelet activation remained noticeably higher at 24 h when using the conventional loading dose (300 mg) of clopidogrel in patients with UA after coronary stenting. This finding highlights the need to evaluate whether a larger loading dose of clopidogrel is a more efficacious and safe for patients with ACS.
